See every side of every news story
Published loading...Updated

Kaftrio eases sinonasal symptoms in children, adolescents

Summary by Cystic Fibrosis News Today
Kaftrio (elexacaftor/tezacaftor/ivacaftor), branded as Trikafta in the U.S., may help clear the nasal passages and surrounding air-filled cavities, known as sinuses, in children and adolescents with cystic fibrosis (CF), according to a real-world study from France. In the MODUL-CF study (NCT04301856), which involved 391 children and adolescents with mild impairment of lung function, those who had blocked noses at the start experienced improvemen…
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Cystic Fibrosis News Today broke the news in on Monday, April 21, 2025.
Sources are mostly out of (0)

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.